Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials-Reference-Cited by-同舟云学术

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

Published:2022-04 Issue:2 Volume:7 Page:100455
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

König D.,Schär S.,Vuong D.,Guckenberger M.,Furrer K.,Opitz I.,Weder W.,Rothschild S.I.,Ochsenbein A.,Zippelius A.,Addeo A.,Mark M.,Eboulet E.I.,Hayoz S.,Thierstein S.,Betticher D.C.,Ris H.-B.,Stupp R.,Curioni-Fontecedro A.,Peters S.,Pless M.,Früh M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. TNM Classification of Malignant Tumours;Brierley,2017

2. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

3. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial;Faivre-Finn;J Thorac Oncol,2021

4. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial;Betticher;J Clin Oncol,2003

5. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial;Stupp;Lancet Oncol,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer (ESPATUE);International Journal of Cancer;2024-08-28

2. Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review;Journal of Thoracic Disease;2024-07

3. The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard;Journal of Thoracic Oncology;2024-06

4. The analysis of current international recommendations for the treatment of patients with stage III non-small cell lung cancer;Grekov's Bulletin of Surgery;2024-05-19

5. Association of pathological response with long-term survival outcomes after neoadjuvant immunotherapy: A meta-analysis;International Immunopharmacology;2024-05